1, , Nohui Health , consumer self-test products of Helicobacter pylori under were first released today. In the early morning, it has been fully launched on , JD.com, , Aikang, , Meituan, , Tmall, , Ping An Health, and several major e-commerce platforms. Youyouguan obtained the Class III medical device registration application approved by the National Medical Products Administration (NMPA) on January 6, 2022. This is the first Helicobacter pylori detection product in China approved by the National Medical Products Administration . The Youyouguan, a subsidiary of Nouhui Health, was launched on the entire network, promoting the public to deeply understand the value of early screening for cancer prevention.
2 and GLY Pharmaceutical announced that subcutaneous injection of PD-L1 antibody ASC22 (enwolizumab) has been approved for IND application in the United States for chronic hepatitis B. ASC22 is a First-in-class subcutaneous injection of PD-L1 antibody for functional cure of chronic hepatitis B. It is also the fastest clinically developed immunotherapy for the treatment of chronic hepatitis B by blocking the PD-1/PD-L1 pathway in the world. In addition, as of November 8, 2021, Gli obtained the exclusive global rights to the development and commercialization of ASC22 from Suzhou Corning Jerry for the treatment of all viral diseases, including hepatitis B. The global sales revenue of ASC22 in all viral diseases belongs to Gli.
3. The drug research and development company Jingtai Technology , driven by intelligence and automation technology, announced that it has reached a strategic cooperation with with , a leader in the domestic biomedical industry, , Zhengdatianqing . The two parties will jointly develop new small molecule drugs for high-difficulty targets for the treatment of malignant tumors. In this cooperation, Jingtai Technology will use its artificial intelligence and high-precision computing chemistry technology to complete the production, evaluation, optimization of compounds, etc., focusing on the discovery and optimization of small molecule anti-tumor innovative drugs.
4 and Dori Pharmaceutical announced that recently, the company signed a "Trust Sales Agreement" with Jinan Kangqiao. Jinan Kangqiao agreed to the company to exclusively entrust the sale of ropivacaine hydrochloride sodium chloride injection (0.2g: 100ml) nationwide and provide a letter of authorization. The entrustment period is from the date of signing of the agreement to December 31, 2026. After the expiration of the term, Jinan Kangqiao reserves the priority of the company's continued exclusive sales of the product nationwide, depending on the sales situation. Multicenter Phase II Clinical Research on the Independently Developed Innovative Drug Carrelizumab combined with Apatinib for Second-Line Treatment of Advanced Esophageal Squamous Cell (CAP 02 Research) was published online in the journal "Lancet·Gastric and Intestinal Disease and Hepatology" sub-job of the internationally renowned medical journal "The Lancet·Gastric and Intestinal Disease and Hepatology". The study was conducted by Professor Wang Feng, the First Affiliated Hospital of Zhengzhou University, as the corresponding author of . The CAP 02 research data released this time once again updated the survival benefit data of second-line treatment of advanced esophageal cancer, which has achieved a new and significant improvement compared with previous chemotherapy plans and immunotherapy monotherapy treatment.
6, and Yubi announced that it has entered into a global cooperation and exclusive license agreement with Eli Lilly Pharmaceuticals to further cooperate in the discovery, development and potential commercialization of new small molecule drugs against undisclosed targets in major diseases such as cardiac metabolic diseases that have not met medical needs. Under the terms of the agreement, Heyu Pharmaceuticals will be responsible for further discovery and development of small-molecule drugs using its proprietary drug development platform that will act on novel and challenging drug targets. Eli Lilly will participate in the research and development work by providing earlier discovery information associated with this target and several additional disease knowledge and skills. If Heyu Pharmaceuticals successfully advances the compound to the end of the agreement, Eli Lilly will have the right to further develop and commercialize it. If Eli Lilly chooses not to promote the compound, Heyu Pharmaceuticals will have the right to further develop and commercialize it.
7, Pejia Medical and JenaValve have entered into a cooperation and license agreement on transcatheter aortic valve replacement products used to treat aortic valve regurgitation. Under these agreements, JenaValve has granted exclusive licenses to the Group for several proprietary transcatheter aortic valve replacement (TAVR) products for the treatment of aortic valve regurgitation and aortic valve stenosis.The Group has the right to develop, manufacture and commercialize related products in Greater China, and the Licensor agrees to provide services and assist the Group in developing the value of related products in the region. The Group has also acquired several preferred shares of JenaValve, equivalent to a small equity investment in the licensor.
8, Deruid (MindRank AI), which focuses on using artificial intelligence to drive drug research and development, announced that it has used its independently developed integrated AI new drug discovery platform Molecule Pro to design and verify 69 new small molecules in 8 months and obtained preclinical candidate compounds targeting a certain Class B G protein-coupled receptor (Class B GPCR) target. At present, the self-developed pipeline has entered the IND-Enabling Studies stage. Historically, the development of Class B GPCR small molecule agonists has proven to be very challenging.
9 and Yuanhua Intelligent completed a round B financing of hundreds of millions of yuan. This round of financing was led by Cornerstone Capital , and the original shareholders Shenzhen Venture Capital and Sequoia China jointly led the investment and continued support, and many well-known investment institutions such as Guoke Jiahe and Wanhui Capital jointly invested. This round of financing will help the company's comprehensive commercial layout of orthopedic surgical robots, accelerate the clinical progress of digestive tract products and transnatural tract surgical robots, and promote the company's self-developed and collaborative robot arm final testing and commercial application.
10, a new tumor immunotherapy drug research and development company Lemang Bio , has completed an angel round of financing of nearly 100 million yuan, led by Tiantu Investment, followed by Wuyuan Capital and Jingtai Technology. This round of funds will be used to accelerate the preclinical research of biomacromolecular drugs that are reprogrammed with immunometabolic metabolism, promote the progress of the new metabolic enhanced CAR-T cell therapeutic drug pipeline to clinical trials, and expand the application scope of the independently developed immunometabolic metabolism reprogramming platform. Leman Bio was founded in July 2021 and focuses on the research and development, production and commercialization of new tumor immunotherapy drugs. The founding team comes from the world's top science and technology colleges, the Federal Institute of Technology of Lausanne, Switzerland (EPFL).
11, Fate Therapeutics announced that the US FDA has approved the IND application for FT536. FT536 is a "ready-to-use" chimeric antigen receptor (CAR) natural killer (NK) cell therapy derived from multiple engineering modifications and inducing pluripotent stem cells (iPSCs). FT536 expresses a novel CAR that specifically targets the A and B (MICA/MICB) α3 domains of class I major histocompatibility complex (MHC)-related proteins. Previous studies have found that antibodies targeting the α3 domain of MICA/B can specifically prevent MICA/B shedding and restore NK cell-mediated immunity.
12. According to preliminary data from a trial released by Israel on Monday, the fourth shot of Pfizer and BioNTech is not enough to prevent infection with the new coronavirus Omickron strain . 154 medical staff from Sheba Medical Center participated in the trial. Two weeks after receiving the fourth dose of Pfizer's new crown vaccine, researchers found that the levels of antibodies in the subjects' bodies increased. But Gili Regev-Yochay, the lead investigator of the trial, said the fourth dose of the Pfizer vaccine only provides part of the defense against the Omickron strain, which, although the vaccine is more effective against the previous strain, has relatively little protection against the Omickron .
13 and Moderna plan to launch a vaccine that combines the new crown-flu-respiratory fusion virus by the end of 2023, hoping to encourage people to receive this comprehensive vaccine once a year. The company's president said in a video conference at the World Economic Forum roundtable on the 17th that his single dose of three-in-one vaccine additives may be released before 2024. Benser said the ideal situation is to launch the market in the fall of 2023. "I don't think this can be achieved in all countries, but some countries may get this vaccine next year. Our goal is to provide one dose of vaccine booster shot every year, which can solve the problem of people not wanting to get two or three doses of vaccines in the winter, and only one dose is needed."
14, Eli Lilly (LLY.N) signed a drug development agreement for metabolic disease with German biotechnology company Evotec (EVO.O). It is understood that Evotec will be responsible for searching for potential drug candidates from identified targets.Eli Lilly will reserve the right to select up to 5 projects under this cooperative relationship for subsequent development and commercialization. In addition, Evotec will receive an advance payment, but the specific amount has not been disclosed. After a series of milestone events of successful development, regulatory licensing and commercialization, the company will also be eligible for additional payments, up to $180 million per project. At the same time, the company also has the opportunity to receive a stratified reward based on net product sales, with a potential total value of up to $1 billion.
15. At the annual JP Morgan healthcare conference held recently, Per Hellsund, CEO of biotechnology company Cybrexa, demonstrated the potential of novel tumor polypeptide coupling drugs (PDC) therapies. Hellsund noted that unlike antibody-drug conjugates (ADCs) focused on antigen , PDC therapy is able to target tumor microenvironment with common characteristics in solid tumors. PDC therapy employs ADC-verified payloads and has the potential to extend the therapy to a new patient population.
Recommended ·Activity
First Yangtze River Delta Single-cell Omics Technology Application Forum
"Medicine Accuracy" series live broadcast: The first issue focuses on the application of MRD in blood tumors
Hot ·Article
Gene Sequencing
[Nature] Challenge evolutionary theory, gene mutations are not random, and one day will help fight cancer!
Cancer Treatment
[Cell Sub-Issue] New Discovery! The "dual personality" protein is not only a "firewall" to resist cancer, but also a "pusher" to promote cancer!
Cancer Treatment
[Nature Sub-Issue] Use alum to eliminate tumors, with accurate and minor side effects! Combined with immune checkpoint inhibitors, it works better!
Gene editing
[Nature Sub-Issue] A new way to edit human cell genes!
Medical Research
[Research] Another benefit of grapes! Eating grapes can increase the diversity of intestinal microbial communities and reduce cholesterolimmunotherapy
[Science] "Father of CAR-T" Carl June and his team achieved new success! One injection of mRNA in the body can produce CAR-T cells for treating heart damage
